Nephros (NEPH) Institutional Ownership $3.99 -0.16 (-3.86%) Closing price 09/4/2025 03:59 PM EasternExtended Trading$4.04 +0.04 (+1.13%) As of 09/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Nephros (NASDAQ:NEPH)CurrentInstitutional OwnershipPercentage41.10%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$855.51KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$145.76K Get NEPH Insider Trade Alerts Want to know when executives and insiders are buying or selling Nephros stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data NEPH Institutional Buying and Selling by Quarter Nephros Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Topline Capital Management LLC477,449$1.95M0.3%+13.1%4.504% 8/15/2025 Elkhorn Partners Limited Partnership14,500$59K0.0%-62.7%0.137% 8/8/2025 Geode Capital Management LLC93,187$381K0.0%+3.2%0.879% 5/12/2025 Bard Associates Inc.143,221$246K0.1%-7.8%1.351% 2/14/2025 Topline Capital Management LLC419,887$617K0.1%N/A3.984% 2/6/2025 Bard Associates Inc.155,271$228K0.1%-9.9%1.473% 8/9/2024 Dimensional Fund Advisors LP17,631$37K0.0%N/A0.167% 4/26/2024 Mesirow Financial Investment Management Inc.15,383$34K0.0%N/A0.146% 2/10/2023 Bard Associates Inc.194,789$225K0.1%-22.7%1.887% 11/15/2022 Elkhorn Partners Limited Partnership50,341$46K0.0%+48.1%0.488% Get the Latest News and Ratings for NEPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022 Bard Associates Inc.263,754$404K0.2%+7.0%2.556% 8/1/2022Cowen Prime Advisors LLC42,500$65K0.0%-47.1%0.412% 5/23/2022 Cantor Fitzgerald L. P.12,813$56K0.0%N/A0.124% 5/11/2022 Bard Associates Inc.246,408$1.08M0.4%+6.0%2.388% 5/10/2022 Elkhorn Partners Limited Partnership23,712$104K0.1%+56.0%0.230% 5/2/2022Cowen Prime Advisors LLC80,400$354K0.1%-87.3%0.780% 2/19/2022 Wexford Capital LP3,650,529$646.53M27.0%N/A35.674% 2/14/2022 Elkhorn Partners Limited Partnership15,200$90K0.1%+78.8%0.149% 2/8/2022Cowen Prime Advisors LLC633,050$3.74M1.3%-4.1%6.186% 2/8/2022Samjo Capital LLC425,000$2.51M1.7%-22.7%4.153% 11/9/2021BlackRock Inc.18,079$158K0.0%-23.0%0.177% 11/2/2021Cowen Prime Advisors LLC660,150$5.79M2.2%+5.4%6.461% 8/17/2021 Wexford Capital LP3,631,197$36.85M5.6%+1.9%35.541% 8/13/2021 Vanguard Group Inc.99,936$1.01M0.0%+3.9%0.978% 8/12/2021 Bard Associates Inc.231,508$2.35M0.8%+5.5%2.266% 8/2/2021 Advisor Group Holdings Inc.4,574$46K0.0%+91,380.0%0.046% (Data available from 1/1/2016 forward) NEPH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NEPH shares? During the previous two years, the following institutional investors and hedge funds held shares of Nephros shares: Topline Capital Management LLC ($1.95M), Geode Capital Management LLC ($381K), Bard Associates Inc. ($246K), Elkhorn Partners Limited Partnership ($59K), and Dimensional Fund Advisors LP ($37K), Mesirow Financial Investment Management Inc. ($34K).Learn more on Nephros' institutional investors. What percentage of Nephros' stock is owned by institutional investors? 41.10% of Nephros' stock is owned by institutional investors. Learn more on NEPH's institutional investor holdings. Which institutional investors have been buying Nephros' stock? The following institutional investors have purchased Nephros' stock in the last 24 months: Topline Capital Management LLC ($475.25K), Dimensional Fund Advisors LP ($17.63K), Mesirow Financial Investment Management Inc. ($15.38K), and Geode Capital Management LLC ($2.90K). How much institutional buying is happening at Nephros? Institutional investors have bought a total of 478,145 shares in the last 24 months. This purchase volume represents approximately $855.51K in transactions. Which of Nephros' major shareholders have been selling company stock? The following institutional investors have sold Nephros stock in the last 24 months: Bard Associates Inc. ($29.15K), and Elkhorn Partners Limited Partnership ($24.42K). How much institutional selling is happening at Nephros? Institutional investors have sold a total of 53,574 shares in the last 24 months. This volume of shares sold represents approximately $145.76K in transactions. Related Companies Biosig Technologies Institutional Ownership Pro-Dex Institutional Ownership LENSAR Institutional Ownership Anteris Technologies Global Institutional Ownership Lakeland Industries Institutional Ownership Lucid Diagnostics Institutional Ownership Profound Medical Institutional Ownership Inovio Pharmaceuticals Institutional Ownership Avita Medical Institutional Ownership Orchestra BioMed Institutional Ownership This page (NASDAQ:NEPH) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
